With its latest acquisition Emergent Biosolutions is tapping into new ways to access public spending.
Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.
The UK has voted to remain in the European Medicines Agency – and it will need to if it wants to avoid delays in drug approvals, data show.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
Approval decisions are looming for an excessive underarm sweating project, and Opdivo plus Yervoy in MSI-high colorectal cancer.
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
It's all about the label for plazomicin, and Array’s Braf-Mek project stacks up well against the competition.